This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biocon has announced the launch of its GLP-1 peptide Liraglutide for diabetes and obesity in the United Kingdom (U.K.).

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Kotak Institutional Equities suggests that high US tariffs on pharmaceuticals are unlikely. They maintain an optimistic ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...